CD274 and non-small cell lung carcinoma: Efficacy of the TTFields therapy plus PD-(L)1 inhibitor combination in metastatic NSCLC will be further assessed in the first-line setting (LUNAR- 2; NCT06216301) [118] and in the PD-(L)1 inhibitor re-challenge setting (LUNAR- 4; NCT06558799) [119].